Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obama's Drug Shortage Efforts Focus On Personnel, Persuasion

This article was originally published in The Pink Sheet Daily

Executive Summary

Executive order gives FDA no new authority, but will allow doubling of shortage staff and likely bolster issue awareness.
Advertisement

Related Content

Drug Shortage Analysis Puts FDA At Loggerheads With GAO
Compounding: How Does FDA Expand Oversight Without Legislation?
Compounding: How Does FDA Expand Oversight Without Legislation?
FDA Shortage Notification Mandate May Not Extend To Biologics
FDA's Drug Shortages Strategy Focuses On Prevention, Not "Empire Building"
Drug Shortages: FDA Wants Advanced Warning; Practitioners Want Even More
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA's Medical Countermeasure Program Among Senate Funding Priorities
To Prevent Drug Shortages, Don't Look To Inspections, FDA Says
Drug Shortage Legislation Gains Momentum With Bipartisan House Bill

Topics

Advertisement
UsernamePublicRestriction

Register

PS072966

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel